Mei Pharma Inc (MEIP) Stock Price, Quote & News

Company Profile

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 369 7100

Website: meipharma.com

Address:

9920 Pacific Heights Blvd., Suite 150, San Diego, United States

whaaatisthisss Aug. 7 at 11:31 AM

$MEIP massive dilution incoming looks like

1 · Reply

Sqeuze_ Aug. 6 at 7:36 PM

$MEIP

0 · Reply

ZorTrades Aug. 6 at 2:53 PM

🚨 Pharma x Crypto 🚨 Nasdaq-listed MEI Pharma $MEIP just acquired $100M of Litecoin (LTC) — 929,548 tokens — making it the first U.S.-listed company to adopt LTC as its primary treasury asset. 👉 Funded via private placement led by: • Charlie Lee (LTC creator, now on MEI’s board) • GSR (now managing the LTC treasury) 📈 Purchase avg: $107.58 📊 Current value: ~$115M 💼 Other backers: Litecoin Foundation, ParaFi, Hivemind, Primitive, RLH, Delta Blockchain MEI cites Litecoin’s 13-year uptime, low fees, fast settlement & integrations with BitPay, PayPal, Robinhood as key reasons for the move. Big statement. Big bet.

0 · Reply

whaaatisthisss Aug. 6 at 2:27 PM

$MEIP i wonder who bought those 9 dollar bags 💀💀💀💀💀💀💀

1 · Reply

Trader1141 Aug. 5 at 8:30 PM

$MEIP would it be too obvious if Kenny made this run? 🤣🤣🤣

0 · Reply

RedHottie Aug. 5 at 8:11 PM

$MEIP https://www.moomoo.com/news/post/56458063?ns_stock_id=208096&report_type=stock&report_id=48679799&main_broker=WwogIDEwMDcKXQ==&skintype=3&src=2&stock_news_tab=news&us_cid=72235814&futusource=news_stock_stockpagenews&client_hour_clock=24&level=1&global_content=%7B%22promote_content%22%3A%22mm%3Apost%3A56458063%22%2C%22invite%22%3A72235814%7D&data_ticket=763c2105711fcc952dcd232f38e29bb4

0 · Reply

BrownMamba824 Aug. 5 at 5:40 PM

$LTC.X bought two more coins to make it a total 30 coins for the pile haha will increase my pile as I go. Supply shock is imminent and will come at some point just how $BTC supply shock is here already. Wait for the institutional investors to buy! $100 million bought of Litecoin by $MEIP already, more should follow suit to get on board and stack as much as possible! Limited supply, don’t be left behind!

2 · Reply

renud Aug. 5 at 3:16 PM

$MEIP And further: "In addition to MEI’s new Litecoin treasury initiative, the Company continues to assess pre-clinical activities with our drug candidate pipeline that includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor, and anticipates commencing further investigational research and development in the next several months."

0 · Reply

renud Aug. 5 at 3:16 PM

$MEIP From today's press release: "MEI plans to formally update its corporate identity in the weeks ahead, reflecting its expanding strategy, which could include the commencement of Litecoin mining activities"

1 · Reply

HodlMyBeerBud Aug. 5 at 3:12 PM

$MEIP Not sure if people realize this company now owns 1.11% of the entire Litecoin Supply Cap. $SBET $MSTR

1 · Reply

MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

Jul 24, 2025, 8:00 PM EDT - 13 days ago

BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode

Jul 22, 2025, 4:35 PM EDT - 15 days ago

MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

Jul 18, 2025, 1:22 PM EDT - 19 days ago

Why Is MEI Pharma Stock Soaring On Friday?

Jul 18, 2025, 8:30 AM EDT - 20 days ago

MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

May 13, 2025, 4:05 PM EDT - 3 months ago

MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position

Feb 12, 2025, 4:12 PM EST - 6 months ago

MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

Nov 12, 2024, 4:05 PM EST - 9 months ago

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

Sep 19, 2024, 4:01 PM EDT - 11 months ago

MEI Pharma Reports Fiscal Year End 2024 Cash Position

Aug 12, 2024, 8:30 AM EDT - 1 year ago

MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives

Jul 22, 2024, 8:30 AM EDT - 1 year ago

MEI Pharma to Consider Strategic Alternatives

May 14, 2024, 10:38 AM EDT - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)

May 9, 2024, 4:02 PM EDT - 1 year ago

MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights

Apr 11, 2024, 8:02 AM EDT - 1 year ago

MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

Apr 11, 2024, 8:00 AM EDT - 1 year ago

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

Apr 10, 2024, 8:00 AM EDT - 1 year ago

MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

$MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia$

Mar 26, 2024, 8:00 AM EDT - 1 year ago

MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Feb 13, 2024, 5:05 PM EST - 1 year ago

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

Jan 16, 2024, 5:00 PM EST - 1 year ago

MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

Dec 11, 2023, 12:00 PM EST - 1 year ago

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

Nov 9, 2023, 4:05 PM EST - 1 year ago

MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights

Nov 8, 2023, 8:00 AM EST - 1 year ago

MEI Pharma to Present at the Stifel 2023 Healthcare Conference

Nov 6, 2023, 4:57 PM EST - 1 year ago

MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock

Nov 2, 2023, 9:00 AM EDT - 1 year ago

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

Nov 1, 2023, 9:00 AM EDT - 1 year ago

MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital

Oct 17, 2023, 5:33 PM EDT - 1 year ago

MEI Pharma Recommends Stockholders Not to Consent

Oct 2, 2023, 6:00 AM EDT - 2 years ago

MEI Pharma Adopts Limited-Duration Stockholder Rights Plan

Sep 28, 2023, 5:00 PM EDT - 2 years ago

MEI Pharma Issues Statement Regarding Anson and Cable Car's Opportunistic Actions

Sep 26, 2023, 7:47 PM EDT - 2 years ago

MEI Pharma, Inc. (MEIP) Q4 2023 Earnings Call Transcript

Sep 26, 2023, 4:02 PM EDT - 2 years ago

MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights

Sep 21, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023

Sep 18, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car

Aug 16, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer

Jul 23, 2023, 2:30 PM EDT - 2 years ago

MEI Pharma Announces Results of Special Meeting of Stockholders

Jul 19, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

Jul 18, 2023, 9:00 AM EDT - 2 years ago

MEI Pharma Responds to Anson and Cable Car

Jul 17, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction

Jul 13, 2023, 4:05 PM EDT - 2 years ago

MEI Pharma Postpones Special Meeting of Shareholders

Jul 11, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals

Jul 7, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals

Jul 5, 2023, 8:30 AM EDT - 2 years ago

ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.

Jul 5, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals

Jun 29, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals

Jun 15, 2023, 12:08 PM EDT - 2 years ago

MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates

Jun 14, 2023, 7:01 PM EDT - 2 years ago

INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI

Jun 13, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor

Jun 2, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D.

Jun 1, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Board of Directors Rejects Unsolicited Proposal

May 30, 2023, 5:40 PM EDT - 2 years ago

MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal

May 23, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

whaaatisthisss Aug. 7 at 11:31 AM

$MEIP massive dilution incoming looks like

1 · Reply

Sqeuze_ Aug. 6 at 7:36 PM

$MEIP

0 · Reply

ZorTrades Aug. 6 at 2:53 PM

0 · Reply

whaaatisthisss Aug. 6 at 2:27 PM

$MEIP i wonder who bought those 9 dollar bags 💀💀💀💀💀💀💀

1 · Reply

Trader1141 Aug. 5 at 8:30 PM

$MEIP would it be too obvious if Kenny made this run? 🤣🤣🤣

0 · Reply

RedHottie Aug. 5 at 8:11 PM

0 · Reply

BrownMamba824 Aug. 5 at 5:40 PM

2 · Reply

renud Aug. 5 at 3:16 PM

0 · Reply

renud Aug. 5 at 3:16 PM

1 · Reply

HodlMyBeerBud Aug. 5 at 3:12 PM

$MEIP Not sure if people realize this company now owns 1.11% of the entire Litecoin Supply Cap. $SBET $MSTR

1 · Reply

HodlMyBeerBud Aug. 5 at 2:47 PM

$MEIP Pretty dope that this gives leveraged litecoin exposure that I can hold in my TFSA. Tax free gains!

0 · Reply

WBOliver81 Aug. 5 at 2:11 PM

$MEIP Unless you are short now, why would you consider to buy @1.50$?

1 · Reply

whaaatisthisss Aug. 5 at 2:05 PM

$MEIP i will buy at 1.50 because they’re gonna burn all of their LTC holdings lol

0 · Reply

WBOliver81 Aug. 5 at 1:44 PM

$MEIP on it‘s way to 100$? :)

0 · Reply

HodlMyBeerBud Aug. 5 at 1:39 PM

$MEIP So PIPE is officially over, that means they will start selling ATM. We may see some NAV compression in the short term, but accumulation is good.

0 · Reply

herewegoagainboys Aug. 5 at 1:35 PM

$MEIP easy wait when you know $15 is coming

0 · Reply

ACInvestorBlog Aug. 5 at 12:11 PM

$MEIP purchased 929,548 Litecoin (LTC) tokens at an average price of $107.58 or around $100M ..... $LTC.X Litecoin is now trading at $126

0 · Reply

mark3rd Aug. 5 at 12:07 PM

$MEIP this news was announced 2 weeks ago.

0 · Reply

ACInvestorBlog Aug. 5 at 12:05 PM

$MEIP announced the acquisition of 929,548 Litecoin (LTC) tokens at an average price of $107.58, successfully launching a major institutional treasury strategy with the LTC treasury now valued at approximately $110.4 million as of August 4, 2025. MEI becomes the first U.S.-listed public company to adopt Litecoin as a primary reserve asset, implementing a new strategy built on digital asset infrastructure and long-term capital innovation.

0 · Reply

DekmarTrades Aug. 5 at 12:02 PM

$MEIP Acquires Litecoin, Launches $100M Institutional Treasury

0 · Reply

ACInvestorBlog Aug. 5 at 12:01 PM

$MEIP Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

1 · Reply

Stock_Catcher Aug. 5 at 12:00 PM

$MEIP Vol

0 · Reply

Market Cap	33.63M
Revenue (ttm)	65.30M
Net Income (ttm)	17.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	27.23%
Debt to Equity Ratio	0.00

Volume	274,100
Avg Vol	1,244,982
Day's Range	N/A - N/A
Shares Out	6.66M
Stochastic %K	17%
Beta	0.37
Analysts	Hold
Price Target	$6.00